Arbutus Biopharma Cp (ABUS) Stock Price, Quote & News

Company Profile

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reaw...

Industry: Biotechnology

Sector: Healthcare

Phone: 267 469 0914

Website: www.arbutusbio.com

Address:

701 Veterans Circle, Warminster, United States

jrothman22 Apr. 25 at 5:41 PM

$ABUS

0 · Reply

jrothman22 Apr. 25 at 2:49 PM

$ABUS

0 · Reply

Grtgooglymoogly Apr. 24 at 8:11 PM

$ABUS The short interest as of 4/15 went up to 17.8 million shares.....up is down, black is white, night is day....

1 · Reply

Heavey Apr. 24 at 8:05 PM

$ABUS something is up but obviously not the SP. To have 8m in volume is very unusual considering the MRNA settlement announcement day also had 8m and that was major news. Waiting patiently for 📰.

3 · Reply

SpaceCityKid Apr. 24 at 8:05 PM

$ABUS Not your textbook hammer, but a huge volume reversal anyway. This action may very well mark the bottom of a large Inverted Head and Shoulder right shoulder. We'll find out shortly.

0 · Reply

Nile1 Apr. 24 at 7:55 PM

$ABUS 7 million , wow, glad I took the chance to add at 4.13 today

0 · Reply

Jdvm Apr. 24 at 7:41 PM

$ABUS volume is 7 million WTF?

2 · Reply

MyBrokenBus Apr. 24 at 7:39 PM

$ABUS -3% per day on decent volu,me, every day this week is impressive. Even for the bus. Next stop please.

0 · Reply

invest5555 Apr. 24 at 7:36 PM

$ABUS change ceo or we are end

0 · Reply

mj6534 Apr. 24 at 7:06 PM

$ABUS I still cb we haven’t moved into the 5’s by now literally no one cares it’s crazy. Market shrugs off everything for us.

0 · Reply

Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B

Mar 23, 2026, 7:30 AM EDT - 4 weeks ago

Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

Mar 3, 2026, 4:46 PM EST - 7 weeks ago

Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant

MRNA

Mar 3, 2026, 4:26 PM EST - 7 weeks ago

Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute

MRNA ROIV

Mar 3, 2026, 4:15 PM EST - 7 weeks ago

Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna

ROIV MRNA

Mar 3, 2026, 4:15 PM EST - 7 weeks ago

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

ROIV MRNA

Mar 3, 2026, 4:15 PM EST - 7 weeks ago

Moderna Resolves Global Patent Litigation with Arbutus/Genevant

MRNA

Nov 13, 2025, 7:30 AM EST - 5 months ago

Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 7, 2025, 8:00 AM EDT - 7 months ago

Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025

Aug 6, 2025, 7:30 AM EDT - 9 months ago

Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jun 25, 2025, 7:30 AM EDT - 10 months ago

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

May 14, 2025, 7:30 AM EDT - 1 year ago

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 7, 2025, 2:01 AM EDT - 1 year ago

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

Apr 23, 2025, 2:01 AM EDT - 1 year ago

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

Mar 27, 2025, 7:56 AM EDT - 1 year ago

Arbutus Biopharma Cuts Workforce by More Than Half, Hires New CFO in Exec Shuffle

Mar 27, 2025, 7:30 AM EDT - 1 year ago

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Mar 3, 2025, 9:15 AM EST - 1 year ago

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

ROIV

Feb 25, 2025, 7:00 AM EST - 1 year ago

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

Jan 13, 2025, 7:30 AM EST - 1 year ago

Arbutus Provides 2025 Corporate and Financial Update

Dec 3, 2024, 11:00 AM EST - 1 year ago

Arbutus Biopharma Transcript: Status Update

Dec 3, 2024, 8:00 AM EST - 1 year ago

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Nov 26, 2024, 7:30 AM EST - 1 year ago

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

Nov 21, 2024, 7:00 AM EST - 1 year ago

Arbutus Biopharma Transcript: Jefferies London Healthcare Conference 2024

Nov 15, 2024, 11:02 AM EST - 1 year ago

Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

Nov 14, 2024, 7:30 AM EST - 1 year ago

Arbutus to Present at Jefferies London Healthcare Conference

Nov 6, 2024, 8:45 AM EST - 1 year ago

Arbutus Biopharma Earnings Call Transcript: Q3 2024

Oct 23, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Oct 15, 2024, 8:16 AM EDT - 1 year ago

Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024

Oct 8, 2024, 1:30 PM EDT - 1 year ago

Arbutus Biopharma Transcript: H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

Sep 10, 2024, 8:30 AM EDT - 1 year ago

Arbutus Biopharma Transcript: Baird's 2024 Global Healthcare Conference

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Arbutus Biopharma Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 3, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Participate in Two Upcoming Investor Conferences

Aug 1, 2024, 8:45 AM EDT - 1 year ago

Arbutus Biopharma Earnings Call Transcript: Q2 2024

Aug 1, 2024, 7:30 AM EDT - 1 year ago

Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 18, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Jun 6, 2024, 11:15 AM EDT - 2 years ago

Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels

Jun 5, 2024, 9:30 AM EDT - 2 years ago

Arbutus Biopharma Transcript: Jefferies 2024 Global Healthcare Conference

Jun 5, 2024, 2:30 AM EDT - 2 years ago

Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure

Jun 3, 2024, 9:50 AM EDT - 2 years ago

Arbutus Distributors Ltd. News Release

May 29, 2024, 7:30 AM EDT - 2 years ago

Arbutus to Participate in Jefferies Global Healthcare Conference

May 22, 2024, 2:00 AM EDT - 2 years ago

Arbutus to Present Imdusiran Data at EASL Congress 2024

May 20, 2024, 3:30 PM EDT - 2 years ago

Arbutus Biopharma Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 17, 2024, 9:00 AM EDT - 2 years ago

Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value

May 14, 2024, 9:30 AM EDT - 2 years ago

Arbutus Biopharma Transcript: The Citizens JMP Life Sciences Conference

May 2, 2024, 8:45 AM EDT - 2 years ago

Arbutus Biopharma Earnings Call Transcript: Q1 2024

May 2, 2024, 7:30 AM EDT - 2 years ago

Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 2, 2024, 7:25 AM EDT - 2 years ago

Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024

Apr 18, 2024, 7:30 AM EDT - 2 years ago

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update

Apr 4, 2024, 8:30 AM EDT - 2 years ago

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna

Mar 12, 2024, 2:05 PM EDT - 2 years ago

Arbutus Biopharma Transcript: Barclays 26th Annual Global Healthcare Conference 2024

Feb 29, 2024, 8:45 AM EST - 2 years ago

Arbutus Biopharma Earnings Call Transcript: Q4 2023

Feb 29, 2024, 7:30 AM EST - 2 years ago

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Feb 15, 2024, 7:30 AM EST - 2 years ago

Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update

Jan 8, 2024, 7:30 AM EST - 2 years ago

Arbutus Announces 2024 Corporate Objectives and Provides Financial Update

Nov 15, 2023, 6:30 AM EST - 2 years ago

Arbutus Biopharma Transcript: 14th Annual Jefferies London Healthcare Conference 2023

Nov 9, 2023, 4:01 PM EST - 2 years ago

Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®

Nov 7, 2023, 8:45 AM EST - 2 years ago

Arbutus Biopharma Earnings Call Transcript: Q3 2023

Nov 7, 2023, 7:30 AM EST - 2 years ago

Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 7, 2023, 7:15 AM EST - 2 years ago

Arbutus Announces CEO, William Collier, to Retire December 31, 2023

Oct 24, 2023, 7:30 AM EDT - 2 years ago

Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update

Oct 18, 2023, 7:30 AM EDT - 2 years ago

Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference

Oct 11, 2023, 8:05 AM EDT - 2 years ago

Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023

Sep 13, 2023, 7:55 AM EDT - 2 years ago

Arbutus Biopharma Transcript: Baird's Global Healthcare Conference 2023

Sep 11, 2023, 4:15 PM EDT - 2 years ago

Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended

Aug 3, 2023, 8:45 AM EDT - 2 years ago

Arbutus Biopharma Earnings Call Transcript: Q2 2023

Aug 3, 2023, 7:30 AM EDT - 2 years ago

Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update

Jul 20, 2023, 7:30 AM EDT - 3 years ago

Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate Update

May 4, 2023, 8:45 AM EDT - 3 years ago

Arbutus Biopharma Earnings Call Transcript: Q1 2023

Mar 2, 2023, 8:45 AM EST - 3 years ago

Arbutus Biopharma Earnings Call Transcript: Q4 2022

Nov 9, 2022, 10:15 AM EST - 3 years ago

Arbutus Biopharma Earnings Call Transcript: Q3 2022

Aug 4, 2022, 8:30 AM EDT - 4 years ago

Arbutus Biopharma Earnings Call Transcript: Q2 2022

jrothman22 Apr. 25 at 5:41 PM

$ABUS

0 · Reply

jrothman22 Apr. 25 at 2:49 PM

$ABUS

0 · Reply

Grtgooglymoogly Apr. 24 at 8:11 PM

$ABUS The short interest as of 4/15 went up to 17.8 million shares.....up is down, black is white, night is day....

1 · Reply

Heavey Apr. 24 at 8:05 PM

$ABUS something is up but obviously not the SP. To have 8m in volume is very unusual considering the MRNA settlement announcement day also had 8m and that was major news. Waiting patiently for 📰.

3 · Reply

SpaceCityKid Apr. 24 at 8:05 PM

$ABUS Not your textbook hammer, but a huge volume reversal anyway. This action may very well mark the bottom of a large Inverted Head and Shoulder right shoulder. We'll find out shortly.

0 · Reply

Nile1 Apr. 24 at 7:55 PM

$ABUS 7 million , wow, glad I took the chance to add at 4.13 today

0 · Reply

Jdvm Apr. 24 at 7:41 PM

$ABUS volume is 7 million WTF?

2 · Reply

MyBrokenBus Apr. 24 at 7:39 PM

$ABUS -3% per day on decent volu,me, every day this week is impressive. Even for the bus. Next stop please.

0 · Reply

invest5555 Apr. 24 at 7:36 PM

$ABUS change ceo or we are end

0 · Reply

mj6534 Apr. 24 at 7:06 PM

$ABUS I still cb we haven’t moved into the 5’s by now literally no one cares it’s crazy. Market shrugs off everything for us.

0 · Reply

mj6534 Apr. 24 at 6:31 PM

$ABUS they did it again as expected. Ran it to 4.70 and back down to 4.15 this is such a joke

0 · Reply

toniotoro Apr. 24 at 5:50 PM

$ABUS they beat it back down to 4.12 again like couple weeks ago, then announced the FDA fast track. What news they gonna sell this coming week?

0 · Reply

MyBrokenBus Apr. 24 at 5:44 PM

$ABUS started buying her almost 6 years ago, at around $4 a share. Maybe the stock win was the friends we made along the way. Perhaps Lindsay Androski can cling to that.

0 · Reply